Table 4.
Retrospective and Nonrandomized Prospective Trials Evaluating PCI
| Study | Primary Therapy | PCI Dose (Gy) | CNS Metastases |
Overall Survival Rates (%) | Median Survival (months) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Observation |
PCI |
P | RR | 95% CI | |||||||
| % | No. of Patients/Total No. | % | No. of Patients/Total No. | ||||||||
| Jacobs 198730 | NA | 30 (2 Gy × 15) | 24 | 14/58 | 5 | 1/20 | .06 | NA | NA | 17 | |
| Skarin 198929 | Trimodality (all NSCLC) | 36 (2 Gy × 18) | 26 | 7/27 | 14 | 1/7 | NA | 31 at 3-5 years 32 | |||
| Strauss 199228 | Trimodality (nonsquam) | 30 (2 Gy × 15) | 12 | 5/41 | 0 | 0/13 | NA | 58 at 1 year 15.5 | |||
| Albain 199527 | Trimodality (all NSCLC) | 36 (2 Gy × 18) | 16 | 16/100 | 8 | 2/26 | .44 | NA | 37 at 2 years;27 at 3 years | 15 | |
| Stuschke 199911 | Trimodality (all NSCLC) | 30 (2 Gy × 15) | 54 | 15/28 | 13 | 6/47 | < .001 | 0.14 | 0.03 to 0.69 | 31 at 3 years | 20 |
| Pottgen 200731 | Trimodality (all NSCLC) | 30 (2 Gy × 15) | 34.7* | 7.8† | NA | 16-18 at 5 years | NA | ||||
Abbreviations: PCI, prophylactic cranial irradiation; RR, relapse rate; NA, not available; NSCLC, non–small-cell lung cancer; nonsquam, nonsquamous.
*
95% CI, 15.7% to 53.7%.
†
95% CI, 0% to 18.5%.